TherapeuticsMD Inc (NASDAQ:TXMD) Expected to Post Earnings of -$0.19 Per Share

Share on StockTwits

Brokerages expect TherapeuticsMD Inc (NASDAQ:TXMD) to post ($0.19) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for TherapeuticsMD’s earnings. The lowest EPS estimate is ($0.21) and the highest is ($0.17). TherapeuticsMD posted earnings per share of ($0.16) during the same quarter last year, which would suggest a negative year over year growth rate of 18.8%. The business is expected to announce its next quarterly earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that TherapeuticsMD will report full-year earnings of ($0.75) per share for the current year, with EPS estimates ranging from ($0.80) to ($0.68). For the next year, analysts forecast that the business will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.63) to $0.05. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.01). The company had revenue of $6.08 million during the quarter, compared to analysts’ expectations of $5.12 million. TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. TherapeuticsMD’s revenue for the quarter was up 60.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.15) earnings per share.

Several equities analysts have recently weighed in on the company. Cowen reduced their price target on TherapeuticsMD from $16.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, June 11th. Noble Financial reiterated a “buy” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research report on Monday, August 12th. JPMorgan Chase & Co. reduced their price target on TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, June 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research report on Wednesday, August 7th. Finally, ValuEngine upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $9.28.

In other TherapeuticsMD news, CEO Robert G. Finizio bought 35,000 shares of TherapeuticsMD stock in a transaction that occurred on Tuesday, August 20th. The stock was acquired at an average cost of $2.74 per share, for a total transaction of $95,900.00. Following the completion of the transaction, the chief executive officer now directly owns 18,253,964 shares in the company, valued at $50,015,861.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C.K. Iv Milligan bought 15,000 shares of TherapeuticsMD stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average price of $3.16 per share, with a total value of $47,400.00. Following the completion of the transaction, the insider now owns 1,472,419 shares of the company’s stock, valued at $4,652,844.04. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 160,549 shares of company stock valued at $465,467. 18.91% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Moors & Cabot Inc. purchased a new position in TherapeuticsMD during the second quarter worth about $25,000. Moloney Securities Asset Management LLC bought a new stake in TherapeuticsMD during the second quarter worth about $27,000. Highland Private Wealth Management bought a new stake in TherapeuticsMD during the second quarter worth about $28,000. H D Vest Advisory Services bought a new stake in TherapeuticsMD during the second quarter worth about $34,000. Finally, Advisor Group Inc. lifted its stake in TherapeuticsMD by 73.2% during the second quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock worth $36,000 after purchasing an additional 5,900 shares during the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

Shares of NASDAQ TXMD traded down $0.02 during mid-day trading on Friday, hitting $2.76. The company had a trading volume of 30,496 shares, compared to its average volume of 3,921,834. The company has a market capitalization of $658.53 million, a price-to-earnings ratio of -4.65 and a beta of 1.90. TherapeuticsMD has a 1 year low of $1.82 and a 1 year high of $6.94. The company has a current ratio of 5.17, a quick ratio of 4.99 and a debt-to-equity ratio of 24.29. The stock’s 50-day moving average price is $2.49 and its 200-day moving average price is $3.85.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Read More: What is the strike price in options trading?

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Merit Medical Systems  PT Lowered to $40.00
Merit Medical Systems PT Lowered to $40.00
Gaming and Leisure Properties  Rating Increased to Hold at Zacks Investment Research
Gaming and Leisure Properties Rating Increased to Hold at Zacks Investment Research
Red River Bancshares  Stock Rating Lowered by Zacks Investment Research
Red River Bancshares Stock Rating Lowered by Zacks Investment Research
Ritter Pharmaceuticals  Downgraded to “Sell” at ValuEngine
Ritter Pharmaceuticals Downgraded to “Sell” at ValuEngine
Maxim Group Reaffirms “Hold” Rating for NXT-ID
Maxim Group Reaffirms “Hold” Rating for NXT-ID
BlackRock TCP Capital  Upgraded at BidaskClub
BlackRock TCP Capital Upgraded at BidaskClub


 
© 2006-2019 Zolmax.